Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Step by step tutorial on how to build a LEGO hammer arcade machine using only standard bricks. This guide explains the full construction process with a working hammer mechanism that measures impact ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...

Vertex Pharmaceuticals’VRTX-0.02%decrease; red down pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...